-
Rodman & Renshaw Cuts Alimera (ALIM) to Market Perform
-
Citi Downgrades Alimera Sciences (ALIM) to Neutral
-
Citi Maintains a 'Buy' Rating on Alimera Sciences (ALIM); Highlights from Meetings with Management
-
Citi Reiterates a 'Buy' Rating on Alimera Sciences (ALIM); Volatility Creates Attractive Entry Point - Several Catalysts Ahead
-
Notable Analyst Rating Changes 06/02: JOYG, JPM, MON, JBL Upgraded; CA, ARST, HI, EXC Downgraded
-
UPDATE - Citi Initiates Coverage on Alimera Sciences (ALIM) with a Buy; Bringing the Spotlight to DME
-
Citi Initiates Coverage on Alimera Sciences (ALIM) with a Buy
-
Alimera Sciences (ALIM) IPO Trades Flat
-
Alimera Sciences (ALIM) IPO Prices at $11, Well Below Expected Range
-
Alimera Sciences (ALIM) Sees 6M Common IPO Price of $15 - $17
-
Alimera Sciences (ALIM) Files $80M IPO
-
Alimera Sciences (ALIM) Files $75M IPO

